{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:17:01Z","timestamp":1783426621890,"version":"3.54.6"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.msard.2026.107267","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:42:21Z","timestamp":1779583341000},"page":"107267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Transitioning from intravenous to subcutaneous ocrelizumab in a high-volume infusion center: A time-and-motion\u2013informed capacity and service-flow analysis"],"prefix":"10.1016","volume":"112","author":[{"given":"Aurora","family":"Zangh\u00ec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Sofia","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rutigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Claudia","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"28","key":"10.1016\/j.msard.2026.107267_bib0015","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2217\/fon-2019-0368","article-title":"Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics","volume":"15","author":"Anderson","year":"2019","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.msard.2026.107267_bib0011","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21315\/mjms2021.28.2.2","article-title":"A Step-by-Step process on sample size determination for medical research","volume":"28","author":"Bujang","year":"2021","journal-title":"Malays. J. Med. Sci."},{"issue":"7","key":"10.1016\/j.msard.2026.107267_bib0002","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.autrev.2019.05.003","article-title":"Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: present and future perspectives","volume":"18","author":"D'Amico","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2026.107267_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.msard.2026.107267_bib0004","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/brainsci10100758","article-title":"Anti-CD20 agents for Multiple sclerosis: spotlight on Ocrelizumab and Ofatumumab","volume":"10","author":"Florou","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.msard.2026.107267_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102974","article-title":"Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: a clinical, economic and patient perspective","volume":"139","author":"George","year":"2025","journal-title":"Cancer Treat. Rev."},{"issue":"18","key":"10.1016\/j.msard.2026.107267_bib0017","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.3390\/cancers15184625","article-title":"Reducing chemotherapy waiting times in the ambulatory setting of a tertiary cancer centre using a design thinking approach","volume":"15","author":"Jen","year":"2023","journal-title":"Cancer. (Basel)"},{"issue":"10","key":"10.1016\/j.msard.2026.107267_bib0009","article-title":"The purpose of time-motion studies (TMSs) in healthcare: A literature review","volume":"14","author":"Kalne","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.msard.2026.107267_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1338546","article-title":"The burden of systemic therapy administration route in HER2+ breast cancer: a systematic review","volume":"15","author":"Landeiro","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.msard.2026.107267_bib0007","doi-asserted-by":"crossref","unstructured":"Mir S., Desroziers K., Saget S., Gherardi A., Groenez A., Paolantonacci J., Regin A.C., Ben Hadj Yahia B., Esnault C., Chouaid C., Voie sous-cutan\u00e9e versus voie intraveineuse en oncologie: pr\u00e9f\u00e9rences et impacts pour les patients et professionnels de sant\u00e9 [Subcutaneous versus intravenous routes in oncology: Preferences and impacts for patients and healthcare professionals]. Bull Cancer. 2025;112(12):1394-1405. French. doi:10.1016\/j.bulcan.2025.07.018.","DOI":"10.1016\/j.bulcan.2025.07.018"},{"key":"10.1016\/j.msard.2026.107267_bib0008","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-7301220\/v1","article-title":"Effects of switching from pertuzumab and trastuzumab administered intravenously as combination subcutaneous formulations on preparation time and medical supply costs","author":"Nakagawa","year":"2025"},{"issue":"9","key":"10.1016\/j.msard.2026.107267_bib0001","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213574","article-title":"Subcutaneous ocrelizumab in patients with multiple sclerosis: Results of the phase 3 OCARINA II Study","volume":"104","author":"Newsome","year":"2025","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2026.107267_bib0018","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1200\/JOP.18.00541","article-title":"Successful implementation of a multidisciplinary Chemotherapy Efficiency initiative at a community hospital","volume":"15","author":"Parkes","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.msard.2026.107267_bib0013","doi-asserted-by":"crossref","unstructured":"Ponzetti C., Canciani M., Farina M., Era S., Walzer S. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clinicoecon Outcomes Res. 2016;8:227-33. doi:10.2147\/CEOR.S97319. Erratum in: Clinicoecon Outcomes Res. 2017 Jan 17;9:75. doi:10.2147\/CEOR.S11883510.2147\/CEOR.S118835.","DOI":"10.2147\/CEOR.S118835"},{"key":"10.1016\/j.msard.2026.107267_bib0014","doi-asserted-by":"crossref","unstructured":"Tran, D., Nguyen, C., Pham, D., & Nguyen, T.(2024). Economic value of subcutaneous versus intravenous trastuzumab administration in the treatment of HER2-positive breast cancer: A systematic review. T\u1ea1p Ch\u00ed Khoa h\u1ecdc Tr\u01b0\u1eddng \u0110\u1ea1i h\u1ecdc Qu\u1ed1c t\u1ebf H\u1ed3ng B\u00e0ng. 61-72. doi:10.59294\/HIUJS.VOL.7.2024.686.","DOI":"10.59294\/HIUJS.VOL.7.2024.686"},{"key":"10.1016\/j.msard.2026.107267_bib0016","doi-asserted-by":"crossref","first-page":"104573","DOI":"10.1016\/j.breast.2025.104573","article-title":"Capacity and cost benefits of subcutaneous versus intravenous pertuzumab\/trastuzumab: The EASE-SC study","volume":"84","author":"Zietse","year":"2025","journal-title":"Breast"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:35:04Z","timestamp":1783424104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826003032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":16,"alternative-id":["S2211034826003032"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107267","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transitioning from intravenous to subcutaneous ocrelizumab in a high-volume infusion center: A time-and-motion\u2013informed capacity and service-flow analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107267"}}